An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)
Phase of Trial: Phase III
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 28 Jun 2017 This trial has been Completed in Hungary (end date: 27 Apr 2017).
- 27 Jun 2017 This trial has been discontinued in Austria.
- 23 Jun 2017 This trial has been Completed in Belgium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History